NMN and Arterial Stiffness: NAD+ for Vascular Flexibility

NMN arterial stiffness research sits at the intersection of NAD+ biology and cardiovascular aging, offering a mechanistically plausible but still emerging strategy for maintaining vascular flexibility. As arteries stiffen with age, systolic blood pressure rises and cardiac workload increases—yet the idea that replenishing NAD+ through nicotinamide mononucleotide (NMN) could slow this process remains largely preclinical. This article examines what the current evidence actually shows, where the gaps are, and what educated consumers should know before drawing conclusions.

What NMN Arterial Stiffness Research Actually Exists

The human clinical literature on NMN and direct arterial stiffness measurements is limited. No published randomized controlled trial to date has used pulse wave velocity (PWV) or augmentation index (AIx) as a primary endpoint in an NMN intervention. However, several human studies have measured related cardiovascular and metabolic parameters that influence vascular health, providing indirect context.

Yoshino et al. (2021) conducted a landmark randomized, placebo-controlled, crossover trial in 25 postmenopausal women with prediabetes. Participants received 250 mg NMN daily for 10 weeks. The primary outcome was muscle insulin sensitivity, which improved significantly. Systolic blood pressure trended lower, though the study was not powered for vascular endpoints. No direct arterial stiffness measures were reported. Yoshino 2021

Igarashi et al. (2022) studied 108 older adults with mild sleep disturbance in a 12-week randomized trial using 250 mg NMN daily. Blood NAD+ metabolite levels rose substantially, and sleep quality improved. Cardiovascular outcomes were not formally assessed, but the study established that long-term NMN supplementation is well-tolerated in an aging population and reliably elevates NAD+—a prerequisite for any vascular benefit hypothesis. Igarashi 2022

Fukamizu et al. (2022) administered 125–250 mg NMN daily to 31 healthy Japanese men for 12 weeks in a randomized, double-blind, placebo-controlled trial. The researchers observed dose-dependent increases in blood NAD+ metabolites and reported no adverse effects. Vascular function was not a measured outcome, but the safety profile and pharmacokinetic data support the feasibility of longer trials targeting arterial stiffness. Fukamizu 2022

The critical takeaway: human NMN arterial stiffness data does not yet exist. Most human studies to date are small-scale, short-duration, and powered for metabolic or sleep endpoints rather than vascular mechanics. The evidence gap is real and should not be understated.

How NMN Arterial Stiffness Mechanisms Work in Preclinical Models

Where human trials fall short, animal and cellular studies provide the mechanistic rationale for investigating NMN in vascular aging. Understanding these pathways clarifies why researchers hypothesize a benefit, even before confirmatory human data exists.

NAD+ and sirtuin signaling. NAD+ serves as the obligate co-substrate for sirtuins, a family of NAD+-dependent deacetylases that regulate vascular endothelial function, inflammation, and oxidative stress. Garten et al. (2015) reviewed the physiological and pathophysiological roles of NAMPT—the rate-limiting enzyme in NAD+ biosynthesis—and established that NAD+ availability declines with age in multiple tissues, including the vasculature. Reduced sirtuin-1 (SIRT1) activity in endothelial cells is associated with impaired nitric oxide production, increased reactive oxygen species, and accelerated vascular senescence. Garten 2015

Mouse models of vascular aging. Mills et al. (2016) demonstrated that long-term NMN administration in aged mice mitigated multiple age-associated physiological declines, including improved blood flow and exercise capacity. In this study, 12-month-old mice received NMN in drinking water for 12 months. Capillary density increased in skeletal muscle, and endothelial-dependent vasodilation improved—suggesting that NMN arterial stiffness benefits in rodents may operate through restored microvascular function and enhanced endothelial flexibility. Mills 2016

Arterial stiffness-specific mechanisms. Stiffening of large arteries arises from collagen cross-linking, elastin fragmentation, vascular smooth muscle cell dysfunction, and chronic low-grade inflammation. NAD+ repletion has been shown in in vitro and animal models to:

• Reduce advanced glycation end-product (AGE) accumulation through enhanced glyoxalase activity
• Decrease vascular cell senescence markers such as p16 and p21 via SIRT1 and SIRT6 activation
• Improve mitochondrial efficiency in vascular smooth muscle cells, reducing oxidative byproducts
• Enhance endothelial nitric oxide synthase (eNOS) phosphorylation, supporting vessel dilation

These mechanisms are biologically coherent. However, translation from mouse to human cardiovascular physiology is historically unreliable. Rodent arteries differ in elastin-to-collagen ratios, blood pressure ranges, and aging trajectories. What reverses vascular aging in a 12-month-old mouse may not scale to a 65-year-old human.

NMN Arterial Stiffness: Human Doses, Forms, and Study Designs Compared

For readers evaluating NMN supplementation in the context of vascular health, the existing human trials provide useful dosing and safety benchmarks—even though arterial stiffness was not their primary endpoint.

<

Study	Population	NMN Dose	Duration	Primary Outcome	Vascular-Related Finding
Yoshino 2021	25 prediabetic women, postmenopausal	250 mg/day	10 weeks	Muscle insulin sensitivity	Systolic BP trended lower (not significant)
Igarashi 2022	108 older adults with sleep disturbance	250 mg/day	12 weeks	Sleep quality, NAD+ levels	Not assessed
Fukamizu 2022	31 healthy Japanese men	125–250 mg/day	12 weeks	NAD+ metabolite levels	Not assessed

Key observations from this comparison:

• Doses between 125 mg and 250 mg daily have been consistently well-tolerated across populations
• Trial durations of 10–12 weeks are sufficient to raise blood NAD+ metabolites but may be too short to detect structural vascular changes
• Arterial stiffness modification likely requires longer intervention periods—6 to 12 months or more—to meaningfully alter collagen deposition or elastin architecture
• No study has yet combined NMN with direct vascular imaging such as carotid-femoral pulse wave velocity (cfPWV) or cardiac MRI for aortic compliance

For context, the related topic of NMN and endothelial function examines how NAD+ supports the lining of blood vessels—a complementary mechanism to arterial stiffness reduction. Similarly, NMN and heart health provides a broader view of cardiovascular research.

Who Benefits Most from NMN Arterial Stiffness Research

Given the current evidence landscape, the most reasonable approach is to identify populations where NMN supplementation aligns with plausible benefit, acceptable risk, and ongoing research interest.

Middle-aged and older adults with elevated pulse wave velocity. Arterial stiffness accelerates after age 50, particularly in individuals with hypertension, diabetes, or chronic kidney disease. These populations have the most to gain from any intervention that preserves vascular compliance, but they also need the strongest evidence before adoption. NMN should be considered experimental, not standard, in this group.

Individuals with prediabetes or insulin resistance. The Yoshino 2021 trial demonstrated that NMN improves muscle insulin sensitivity in prediabetic women. Insulin resistance and hyperglycemia are independent drivers of arterial stiffening through AGE formation and collagen glycation. For this population, NMN may offer dual metabolic and vascular relevance, though direct arterial stiffness data remain absent.

Those with low baseline NAD+ status. Aging, obesity, and chronic inflammation all reduce tissue NAD+ levels. Individuals with these characteristics may experience greater relative increases in NAD+ metabolites with supplementation, though this does not automatically translate to improved vascular mechanics. NMN and exercise capacity research suggests that physical fitness and NAD+ status interact, with more sedentary individuals showing larger performance gains.

People already optimizing cardiovascular risk factors. NMN is not a substitute for blood pressure control, lipid management, smoking cessation, or exercise. However, for individuals who have addressed these fundamentals and seek additional strategies, NMN represents a mechanistically grounded, low-risk candidate awaiting stronger trial evidence.

It is worth noting that hydrogen water and heart health research offers a parallel antioxidant strategy with some overlapping cardiovascular targets, though the mechanisms differ substantially.

Practical Takeaways for NMN Arterial Stiffness Considerations

• Human evidence directly linking NMN to reduced arterial stiffness does not yet exist; all conclusions rely on mechanistic inference and animal data
• Doses of 250 mg daily have been safely used in trials lasting up to 12 weeks; longer durations are biologically plausible but not yet formally tested for vascular endpoints
• NMN reliably raises blood NAD+ metabolites in humans, which supports the mechanistic premise for vascular benefit, but biomarker elevation does not guarantee clinical outcome improvement
• Arterial stiffness is best monitored clinically through carotid-femoral pulse wave velocity (cfPWV); any supplement strategy should be paired with periodic measurement if vascular health is the primary concern
• NAD+ repletion works through sirtuin activation, mitochondrial support, and reduced oxidative stress—pathways that are also supported by exercise, caloric restriction, and adequate sleep
• PEPAX NMN provides 500 mg per capsule, a dose above the 250 mg used in most human trials; individuals interested in vascular health applications should consider this in consultation with a clinician, given the absence of dose-response arterial stiffness data

Bottom Line on NMN Arterial Stiffness Evidence

The hypothesis that NMN reduces arterial stiffness is mechanistically compelling, grounded in robust preclinical data on NAD+ biology, sirtuin signaling, and vascular aging. However, the human evidence required to validate this hypothesis—randomized trials with direct arterial stiffness endpoints—has not yet been conducted. Most human studies to date are small-scale, short-duration, and focused on metabolic or sleep outcomes rather than vascular mechanics. For educated consumers, NMN remains a promising but unproven strategy for arterial flexibility, best viewed as part of a broader cardiovascular optimization plan rather than a standalone solution.

---

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels in healthy subjects with mild sleep disturbance." NPJ Aging. 2022;8(1):5. [Source]
3. Fukamizu Y, et al. "Effects of orally administered nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Scientific Reports. 2022;12:6134. [Source]
4. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism. 2016;24(6):795–806. [Source]
5. Garten A, et al. "Physiological and pathophysiological roles of NAMPT and NAD metabolism." Nature Reviews Endocrinology. 2015;11(9):535–546. [Source]

---

---